- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
FDA
FDA says potential diabetes drug may cause cancer
July 18, 2011
Bloomberg NewsDapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients
excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar
drugs.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
MoreLilly confident of FDA approval for Amyvid, Lechleiter says
March 9, 2011
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify
plaque in the brain associated with Alzheimer’s disease.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MoreLilly, Bristol-Myers halt enrollment in lung-cancer trial
February 2, 2011
J.K. WallEli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung
cancer drug over concerns about patients developing blood clots.
MoreLilly product gets boost; Wall Street yawns
January 26, 2011
J.K. WallEli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease,
but so far analysts are unimpressed.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreLilly partner moves up timetable for diabetes drug
January 11, 2011
Bloomberg NewsAmylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable
and submit a heart-safety study to regulators by the end of 2011, its CEO said.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreLilly wins approval of antidepressant Cymbalta for pain
November 4, 2010
Bloomberg NewsThe Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions,
which could mean another $500 million in annual sales for Lilly, an analyst estimates.
MoreAnalysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreFDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly falls short on 'field goal' attempt
October 13, 2010
J.K. WallEli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing
drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
MoreEndocyte's $86M IPO plan a boon for Indiana, investors
August 28, 2010
Greg AndrewsVenture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
It's also across the street from Fogo de Chao and Morton's....
Yep, the haters are trying to make good news bad. I guess it is hard to get people to believe the series is dying when they are gaining new sponsors.
David Copperfield! I remember watching his specials on TV when I was little.
Don't forget this is next to an MMA gym, a pawn shop, and some abandoned spaces.
Good project for Zionsville - A group who has owned the property for many years has waited and worked patiently to bring highest and best use development to a major corridor, and mix that in with the great downtown you have. Win Win. All the Best to Pittman Partners and Zionsville.